Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

We can scratch number 1 from the list for the foreseeable future.

I had written Dr. Berger and BoD on the neurodegenerative diseases possibilities, and heard back from HB just now (Sunday night). His response was quite detailed and complete. Essentially, there is not enough evidence in studies and literature for Ariad to invest in any of these indications or find partners. The have a few ongoing pre-clinical collaborations, but there is no detectable momentum.

Separately, packaging and pricing issues are also detriments.

It's not 100% closed, and the patent stakes out a claim. The companies focus will remain on oncology indications.